A Robust Automated Measure of Average Antibody Staining in Immunohistochemistry Images

被引:119
作者
Choudhury, Kingshuk Roy [1 ]
Yagle, Kevin J. [2 ]
Swanson, Paul E. [4 ]
Krohn, Kenneth A. [2 ]
Rajendran, Joseph G. [2 ,3 ]
机构
[1] Natl Univ Ireland Univ Coll Cork, Dept Stat, Cork, Ireland
[2] Univ Washington, Dept Radiol, Seattle, WA 98195 USA
[3] Univ Washington, Dept Radiat Oncol, Seattle, WA 98195 USA
[4] Univ Washington, Dept Pathol, Seattle, WA 98195 USA
基金
美国国家卫生研究院; 爱尔兰科学基金会;
关键词
IHC; cancer markers; automated scoring; PROGNOSTIC BIOMARKERS; RECEPTOR STATUS; BREAST-CANCER;
D O I
10.1369/jhc.2009.953554
中图分类号
Q2 [细胞生物学];
学科分类号
071013 [干细胞生物学];
摘要
Identifying and scoring cancer markers plays a key role in oncology, helping to characterize the tumor and predict the clinical course of the disease. The current method for scoring immunohistochemistry (IHC) slides is labor intensive and has inherent issues of quantitation. Although multiple attempts have been made to automate IHC scoring in the past decade, a major limitation in these efforts has been the setting of the threshold for positive staining. In this report, we propose the use of an averaged threshold measure (ATM) score that allows for automatic threshold setting. The ATM is a single multiplicative measure that includes both the proportion and intensity scores. It can be readily automated to allow for large-scale processing, and it is applicable in situations in which individual cells are hard to distinguish. The ATM scoring method was validated by applying it to simulated images, to a sequence of images from the same tumor, and to tumors from different patient biopsies that showed a broad range of staining patterns. Comparison between the ATM score and manual scoring by an expert pathologist showed that both methods resulted in essentially identical scores when applied to these patient biopsies. This manuscript contains online supplemental material at http://www.jhc.org. Please visit this article online to view these materials. (J Histochem Cytochem 58:95-107, 2010)
引用
收藏
页码:95 / 107
页数:13
相关论文
共 16 条
[1]
Allred DC, 1998, MODERN PATHOL, V11, P155
[2]
ALLRED DC, 2008, ESTROGEN PROGESTERON
[3]
DANGERS OF USING OPTIMAL CUTPOINTS IN THE EVALUATION OF PROGNOSTIC FACTORS [J].
ALTMAN, DG ;
LAUSEN, B ;
SAUERBREI, W ;
SCHUMACHER, M .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (11) :829-835
[4]
[Anonymous], 1998, BIOSTATISTICAL ANAL
[5]
Bast RC, 1998, J CLIN ONCOL, V16, P793
[6]
Prognostic biomarkers in head and neck cancer [J].
Grandis, Jennifer R. .
CLINICAL CANCER RESEARCH, 2006, 12 (17) :5005-5006
[7]
Testing for HER2 status [J].
Hanna, W .
ONCOLOGY, 2001, 61 :22-30
[8]
Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer [J].
Harvey, JM ;
Clark, GM ;
Osborne, CK ;
Allred, DC .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) :1474-1481
[9]
Cytometrical image analysis for immunohistochemical hormone receptor status in breast carcinomas [J].
Hatanaka, Y ;
Hashizume, K ;
Nitta, K ;
Kato, T ;
Itoh, I ;
Tani, Y .
PATHOLOGY INTERNATIONAL, 2003, 53 (10) :693-699
[10]
USE OF AVIDIN-BIOTIN-PEROXIDASE COMPLEX (ABC) IN IMMUNOPEROXIDASE TECHNIQUES - A COMPARISON BETWEEN ABC AND UNLABELED ANTIBODY (PAP) PROCEDURES [J].
HSU, SM ;
RAINE, L ;
FANGER, H .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1981, 29 (04) :577-580